AI in Pharma: Risk‑Based Innovation, Not a Compliance Time Bomb
Artificial intelligence is already embedded across pharma and biotech, supporting literature reviews, data analysis, training development and operational efficiency.
Yet in many organisations, adoption has moved faster than governance. Policies lag behind behaviour, leaving leadership teams with a widening gap between innovation and control.
The biggest compliance risk is not that AI is being used. It’s how it is being used. A risk‑based approach to AI governance allows organisations to innovate with confidence while protecting reputation and regulatory credibility.
The Real Risk: Losing Visibility
Banning AI might appear safe, but in practice it often increases risk. When use is prohibited, behaviours don’t stop – they go underground. Teams rely on personal devices, public tools and undocumented shortcuts. Shadow workflows emerge, audit trails vanish, and leadership loses oversight.
Effective compliance isn’t about saying “no”. It’s about making AI use visible, controlled and owned.
Where AI Adds Genuine, Low‑Risk Value
AI can deliver significant efficiency gains when it supports rather than replaces human judgement. Lower‑risk use cases typically include:
- Summarising internal documents
- Supporting literature searches (with human verification)
- Early drafting of SOPs or training materials
- Structuring internal communications or presentations
- Spotting high‑level trends in large datasets
In each case, accountability remains with a named individual and outputs are reviewed before use. Controls are proportionate to risk, not unnecessarily restrictive.
When AI Becomes High Risk
Risk escalates quickly when AI is used to generate or influence regulated decisions. High‑risk red flags include:
- Promotional or medical content creation
- Responses to HCPs or medical information enquiries
- Interpretation of patient‑level or confidential data
- Automated decisions affecting safety or access
In these scenarios, loss of control becomes the core issue – from hallucinated facts to blurred accountability. If AI output could trigger regulatory scrutiny, it cannot be the final author.
What Risk‑Based AI Governance Looks Like
Risk‑based AI governance enables innovation rather than slowing it. In practice, this means:
- Clear classification of AI use cases by risk
- Defined permitted and prohibited activities
- Explicit human‑in‑the‑loop requirements
- Clear rules on data that must not be entered into AI tools
- Documentation and audit trails proportionate to risk
The principle is simple: the higher the risk, the stronger the controls.
AI Risk Is a Leadership Issue
AI risk is not an IT problem. It’s a leadership one. Regulators care about outcomes, accountability and behaviours, not tools.
Boards and executives must set risk appetite and ownership. Compliance and Medical define guardrails. IT manages tools and data security. Line managers reinforce daily behaviours.
When ownership is unclear, governance is either ignored, over‑engineered, or even bypassed completely.
Innovation and Compliance Can Co‑Exist
The most mature organisations are no longer asking “Can we use AI?”
They are asking:
“Where does AI genuinely add value and what controls make that use defensible?”
Asking that question could be the difference between risk‑based innovation and a future compliance failure.
How GRC Catalyst Helps
GRC Catalyst supports pharma and biotech leaders to design pragmatic, risk‑based AI governance frameworks that enable innovation while protecting regulatory credibility, from use‑case classification and leadership accountability to training and audit‑ready controls.
If you’d like to explore what defensible AI governance could look like in your organisation, let’s talk.
Disclosure
The concepts and ideas in this article are mine or have been referenced; I developed the body of the text and conducted the final editorial check. I used AI as a tool for research, to improve the flow and grammar of the article, and to check for factual inaccuracies..
